Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Reddington H, Ballinger Z, Guart J, Emmerick I, Crawford A, Maxfield M, Uy K, Lou F. National adoption of robotic-assisted thoracoscopic surgery for oncologic lung resections. J Robot Surg. 2025 Sep 04; 19(1):557.
-
Dora D, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk? B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. Front Immunol. 2025; 16:1543817.
-
Osataphan S, Awidi M, Jan YJ, Gunturu K, Sundararaman S, Viray H, Frankenberger E, Mariano M, O'Loughlin L, Piper-Vallillo A, Stafford K, Kolnick A, Ghazalah H, Sehgal K, Patti ME, Costa D, Lam P, Rangachari D. Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer. 2024 Dec; 198:108023.
-
Babu S, Horowitz M, Delgado-Coka LA, Roa-Pe?a L, Akalin A, Escobar-Hoyos LF, Shroyer KR. Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer. Pathol Res Pract. 2024 Nov; 263:155643.
-
Watkins AA, Rizvi TZ, Lopez E, Shehata D, Ssemaganda H, Lin Z, Stock CT, Moffatt-Bruce SD, Servais EL. Trends and comparative outcomes between operative approaches for segmentectomy in lung cancer. J Thorac Cardiovasc Surg. 2025 Mar; 169(3):745-752.e2.
-
Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, J?nne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024 Jul 05; 29(7):609-618.
-
Burks EJ, Sullivan TB, Rieger-Christ KM. Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial. Cancer Biomark. 2025 Jan; 42(1):CBM230452.
-
McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329.
-
Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024 Mar; 199:113530.
-
Lamb CR, Rieger-Christ KM, Reddy C, Huang J, Ding J, Johnson M, Walsh PS, Bulman WA, Lofaro LR, Wahidi MM, Feller-Kopman DJ, Spira A, Kennedy GC, Mazzone PJ. A Nasal Swab Classifier to Evaluate the?Probability of Lung Cancer in Patients With Pulmonary Nodules. Chest. 2024 04; 165(4):1009-1019.